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Background: Grebe dysplasia, Hunter-Thompson dysplasia, and du Pan dysplasia constitute a spectrum of skeletal
dysplasias inherited as an autosomal recessive trait characterized by short stature, severe acromesomelic shortening
of the limbs, and normal axial skeleton. The majority of patients with these disorders have biallelic loss-of-function
mutations of GDF5. In single instances, Grebe dysplasia and a Grebe dysplasia-like phenotype with genital anomalies
have been shown to be caused by mutations in BMPR1B, encoding a GDF5 receptor.
Methods: We clinically and radiologically characterised an acromesomelic chondrodysplasia in an adult woman
born to consanguineous parents. We sequenced GDF5 and BMPR1B on DNA of the proposita. We performed 3D
structural analysis and luciferase reporter assays to functionally investigate the identified BMPR1B mutation.
Results: We extend the genotype-phenotype correlation in the acromesomelic chondrodysplasias by showing that
the milder du Pan dysplasia can be caused by a hypomorphic BMPR1B mutation. We show that the homozygous
c.91C>T, p.(Arg31Cys) mutation causing du Pan dysplasia leads to a significant loss of BMPR1B function, but to a
lesser extent than the previously reported p.Cys53Arg mutation that results in the more severe Grebe dysplasia.
Conclusions: The phenotypic severity gradient of the clinically and radiologically related acromesomelic chondrodysplasia
spectrum of skeletal disorders may be due to the extent of functional impairment of the ligand-receptor pair
GDF5-BMPR1B.
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The acromesomelic dysplasias (ACD) constitute a rare sub-
group of osteochondrodysplasias that are characterised by
short stature and shortened limbs with anomalies of the
hands and feet [1]. According to the 2010 revision of the
nosology and classification of genetic skeletal disorders,
five ACD subgroups are recognised, namely the severe
Grebe dysplasia (including Grebe (OMIM #200700) and
Hunter-Thompson (OMIM #201250) types), the milder du
Pan dysplasia (OMIM #228900), a Grebe dysplasia-like
phenotype with genital anomalies (OMIM #609441), as
well as the ACD types Maroteaux (OMIM #602875) and
Osebold-Remondini (OMIM 112910) (the latter two types
will not be considered further here) [2]. While Grebe* Correspondence: guntram.borck@uni-ulm.de
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creativecommons.org/publicdomain/zero/1.0/dysplasia is characterised by severe distal limb anomalies
with rudimentary fingers and toes, there is mild short stat-
ure and milder limb involvement in du Pan dysplasia, in-
cluding fibular hypoplasia and complex brachydactyly.
Both Grebe dysplasia and du Pan dysplasia are auto-
somal recessive disorders and can be caused by biallelic
loss-of-function mutations of GDF5 (previously known
as CDMP1), encoding the growth and differentiation fac-
tor 5 [3–6]. GDF5 belongs to the bone morphogenetic
protein (BMP) family and binds to the BMP receptors
BMPR1A and BMPR1B, with a preference for BMPR1B
[7]. Consistent with this ligand-receptor interaction,
ACD cannot only be caused by GDF5 mutations, but in
rare cases also by loss-of-function BMPR1B mutations.
Indeed, Demirhan and colleagues identified a homozy-
gous truncating mutation of BMPR1B underlying a
Grebe dysplasia-like phenotype with genital anomalies
(absent ovaries, hypoplastic uterus, hypergonadotropicrticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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previously reported a homozygous missense mutation
(p.Cys53Arg) and a homozygous nonsense mutation
(p.Trp219*) of BMPR1B in Grebe dysplasia [9]. Func-
tional analysis of the p.Cys53Arg missense alteration
indicated that the mutant receptor had reduced localisa-
tion at the cell membrane, reduced activation by GDF5
binding and no effect on cell differentiation upon over-
expression in an in vitro chondrogenesis assay, consist-
ent with loss of function [9]. Here we have identified
and characterised a hypomorphic BMPR1B missense al-
teration that causes du Pan dysplasia.
Methods
Clinical investigation and molecular analyses
The clinical evaluation was performed at the Depart-
ment of Medical Genetics, Hospital Erasme, Brussels,
Belgium, and the Institut de Pathologie et de Génétique,
Gosselies, Belgium, and research was performed follow-
ing a protocol approved by the University of Ulm Ethics
Committee. After obtaining written informed consent
for participation in the study, including consent to re-
port individual patient data, we sequenced the coding
exons and splice sites of GDF5 (NM_000557.2) and
BMPR1B (NM_001256794.1) on genomic DNA after
PCR amplification. Primer sequences are available on re-
quest. PCR products were sequenced on an ABI 3730
DNA Analyzer with BigDye chemistry v3.1 (Applied Bio-
systems). Sequence traces were assembled, aligned, and
analyzed with the Seqman software (DNASTAR Laser-
gene). The BMPR1B intragenic short tandem repeat
(STR) markers D4S2278 and BMPR1B-STR2 (forward
primer 5’-TTAAAAGTAAAGACCATATAAAGG-3’; re-
verse primer 5’-GGACTTAAAACTCTGCAACAAC-3’)
were genotyped after PCR amplification on an ABI 3730
DNA Analyzer. Single nucleotide polymorphism (SNP)
array genotyping was performed using a Genome-Wide
Human SNP Array 6.0 (Affymetrix), according to the
manufacturer´s instructions. Linkage analysis and haplo-
type reconstruction were performed using the program
ALLEGRO [10]. Haplotypes were presented graphically
with HaploPainter [11]. All data handling was performed
using the graphical user interface ALOHOMORA [12].
Structural analysis
The BMPR1B substitutions Arg31Cys (identified here)
and Arg31His (present at low frequency in public data-
bases; rs200035802) were modeled on the basis of the
crystal structure of the human BMPR1B extracellular
domain bound to human GDF5 (PDB entry 3EVS, [13]).
The side chain of Arg31 was exchanged for either a cyst-
eine or histidine using the ProteinDesign tool of the soft-
ware Quanta2008 (MSI Accelrys) and rotamer searches
were performed to identify the most likely side chainconformation. Potential alternative disulfide connectivi-
ties were analyzed by performing energy minimization
runs in vacuo employing only geometrical energy terms.
Cloning of BMPR1B expression constructs
The expression constructs for HA-tagged Bmpr1b WT
and Bmpr1b Cys53Arg were previously described [9].
HA-tagged Bmpr1b WT in pSLAX13 was used as a tem-
plate for in vitro mutagenesis to introduce the mutation
coding for Arg31Cys (Primer forward 5´-ctcggcccaag
atcctaTgttgtaaatgccaccac-3´, reverse 5´-gtggtggcatttacaac
Ataggatcttgggccgag-3´) or coding for Arg31His (Primer
forward 5´-cggcccaagatcctacAttgtaaatgccaccac-3´, re-
verse 5´-gtggtggcatttacaaTgtaggatcttgggccg-3´). Inserts
were subcloned into the expression vector pCS2+ after
ClaI restriction.
Luciferase reporter gene assay
NIH/3 T3 cells (ATCC) were seeded in a 96-well plate in
growth medium (DMEM 4.5 g/l glucose (Lonza), 10 % FBS
superior (Biochrom), 2 mM L-glutamine (Lonza)) and
transfected 24 h later using Lipofectamine 2000 (Invitrogen,
Life Technologies) following the manufacturer´s instruc-
tions. Cells were transfected in growth medium with the
control vector pCS2+ or one of the Bmpr1b variants in
pCS2+ together with the BRE luciferase reporter construct
BRE-pLG3ti [14] and the Renilla luciferase normalization
vector pRL-TK (Promega). After 18 h cells were stimulated
with 2 nM human recombinant GDF5 (Biopharm) in
serum-reduced medium (DMEM 4.5 g/l glucose (Lonza),
1 % FBS superior (Biochrom), 2 mM L-glutamine (Lonza)).
40 h after transfection cells were lysed in potassium phos-
phate buffer (9 mM potassium di-hydrogen phosphate,
91 mM di-potassium phosphate, 0.2 % Triton-X-100) and
dual luciferase activity was measured as described previ-
ously [15] using the Mithras LB 940 (Berthold Technolo-
gies). For statistical analysis GraphPad Prism 5 (GraphPad
Software, Inc.) was used.
Confocal microscopy
NIH/3 T3 cells were seeded into a 24-well plate in
growth medium on cover glasses (Marienfeld). 24 h later
Bmpr1b expression vectors were transfected into the
NIH/3 T3 cells using Lipofectamine 2000 (Invitrogen,
Life Technologies) following the manufacturer´s instruc-
tions. Another 24 h later cells were incubated under
serum free conditions (DMEM 4.5 g/l glucose (Lonza),
2 mM L-glutamine (Lonza)) for 1 h, subsequently fixed
with 4 % paraformaldehyde in PBS and blocked in PBS
containing 10 % FBS superior (Biochrom) over night.
Non-permeated cells were incubated with a rabbit anti-
HA antibody (H6908, Sigma-Aldrich; diluted 1:100 in
PBS containing 10 % FBS superior (Biochrom)) for 1 h.
After washing with PBS the cells were incubated with
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Molecular Probes Life Technologies) and with DAPI
(Invitrogen, Life Technologies) for 1 h. The cover glasses
containing stained cells were mounted on microscope
slides (‘SuperFrost Plus’, Menzel) using Fluoromount-G
(Southern Biotech). Confocal microscopy was performed
using Zeiss Axio Imager.M2 equipped with a LSM700
confocal module (Carl Zeiss, 63-fold magnification).
Results
Clinical evaluation
The proposita was a 38 year-old woman who presented
to the genetics clinic because of short stature and limb
anomalies. She is the 11th child (of 11) born to first
cousin parents originating from Morocco (Fig. 1a). One
of her sisters and two of her brothers are similarly af-
fected; they live in a remote area of Morocco with very
limited access to medical care and no detailed clinical
information, skeletal radiographs or DNA were available
from them. The parents were unaffected; maternal
height was 160 cm and paternal height 180 cm.A
C
Fig. 1 BMPR1B p.Arg31Cys causes a du Pan dysplasia-like phenotype. a Ped
and feet of the proposita. Note short, malformed fingers and hypoplastic to
32 years showing abnormalities of metacarpals and phalangeal bones. Ap
extremities including feet; ap and lateral view showing abnormalities of tar
showing parts of BMPR1B exon 1. The homozygous c.91C>T, p.(Arg31Cys) m
chromatograms indicate amino acids in single letter codeThe proposita had disproportionate short stature with
a height of 148 cm (− 2.7 SD) and mild acromesomelic
limb shortening. The fibulae were not palpable. She had
short fingers and abnormal finger joints with deviations
(Fig. 1b). Fingers II and V were most severely affected.
Finger nails were normal. The toes were hypoplastic, in
particular toes III to V, with broad and short toe nails
(Fig. 1b). Radiological examination for the hands re-
vealed proximal symphalangism and dysplastic middle
phalanges (absence of the middle phalanx in the index
finger, hypoplasia of the middle phalanges with narrow
proximal phalangeal joints in the middle and ring fin-
gers, and absence of the middle phalanx and long prox-
imal phalanx in the little finger), shortening of the first
metacarpal and a single long phalanx in the thumb,
short proximal phalanx of the index finger and narrow
carpal joint spaces (Fig. 1c). Radiographs of the feet
showed similar findings, including a single misshapen
phalanx in the great toe, hypoplasia of the middle phal-
anx in the second toe, absence of the middle phalanges
in the third, fourth, and fifth toes, and calcaneocuboidB
D
igree of the family. The proposita is indicated by an arrow. b Hands
es. c Radiographs of the proposita. Ap view of hands at the age of
view of the knees: note absent fibulae. Radiographs of the lower
sal, metatarsal and phalangeal bones. d Sequence chromatograms
utation is indicated by an arrow. Letters below the sequence
Stange et al. Orphanet Journal of Rare Diseases  (2015) 10:84 Page 4 of 6fusion (Fig. 1c). The ankle joints were mal-aligned. The
fibula was totally missing (Fig. 1c).
The proposita reported normal puberty with menarche
at 13 years and regular menstrual cycles. Abdominal
ultrasound was normal with the presence of a uterus
and ovaries of normal size and shape. There was no
hypergonadotropic hypogonadism with normal LH, FSH,
estradiol and progesterone.
Mutation identification
Because the clinical presentation was compatible with du
Pan dysplasia we first sequenced the coding region and
exon-intron boundaries of GDF5 and identified no muta-
tion. Upon sequencing of BMPR1B we detected a homozy-
gous c.91C>T (p.Arg31Cys) variant (Fig. 1d). No DNA
from other affected and unaffected family members was
available to test for co-segregation with du Pan dysplasia.
Consistent with BMPR1B being located in an autozygous
region, genotyping of two highly polymorphic BMPR1B in-
tragenic STRs showed homozygosity and SNP array geno-
typing confirmed a large (20.2 Mb) homozygous region at
the BMPR1B locus in the proposita, defined by the flanking
SNPs rs2131361 and rs17278473 (data not shown). Residue
Arg31 is moderately conserved in BMPR1B orthologs. It is
conserved e.g., in mouse, rat, cat, dog, and platypus; it is re-
placed with a histidine in e.g., green monkey, panda and
hedgehog, and with a glutamine in e.g., opossum and tur-
tles. None of the >60 species included in the UCSC mul-
tiple species alignment has a cysteine at the corresponding
position. While the ExAC browser (http://exac.broadinsti
tute.org/) lists a p.Arg31His substitution (rs200035802)
with an allele frequency of 18/121.162, p.Arg31Cys was
only identified in 1/121.150 alleles, compatible with
p.Arg31Cys being disease causing. Consistently, PolyPhen-
2 [16] predicts p.Arg31Cys as “possibly damaging” and
p.Arg31His as “benign” (both variants are predicted “not
tolerated” by SIFT [17]). Finally, no variant predicting
p.Arg31Cys was identified in exome sequences from 30
Moroccan patients with unrelated disorders (Jaber Lyahyai,
personal communication) and no p.Arg31Cys homozy-
gotes or heterozygotes were present in the 5,718 exomes
included in the Institut Imagine (Paris) in-house database,
which is enriched for exomes of Maghrebian individuals,
and contains a very conservatively estimated number of
Moroccan exomes of 33.
Structural modeling of the BMPR1B mutation p.Arg31Cys
Arg31 is located at the beginning of the BMPR1B ligand
binding domain (LBD), suggesting that the p.Arg31Cys
mutation may interfere with GDF5 binding. We modeled
p.Arg31Cys using the structure of human BMPR1B bound
to human GDF5 [13]. Residue 31 shares no direct contact
with the ligand GDF5 and is more than 10 Å remote
(Fig. 2a). Thus, a direct impact on the GDF5-receptorbinding by loss of direct van der Waals interactions seems
unlikely. In our in silico models the exchange of Arg31 by
cysteine however places an unpaired thiol group in close
proximity to Cys32, Cys47, Cys53, and Cys71 (Fig. 2b)
thereby possibly allowing for an alternate disulfide net-
work. The model of such a rearranged disulfide bond net-
work suggested that it will not necessarily destroy the
BMP receptor’s three-finger toxin fold, but may introduce
conformational changes in the disulfide-bond connected
loops in particular of the β1β2-loop (Fig. 2c). As this loop
is engaged in contacts with GDF5 and has been implicated
in ligand recognition and binding (Fig. 2a) [13] even such
smaller changes may affect ligand-receptor interaction.
The effects of p.Arg31His seem subtler as those predicted
for p.Arg31Cys (Fig. 2d).
Functional analyses of mutant BMPR1B receptors
We performed a luciferase reporter gene assay using the
SMAD dependent BRE reporter to determine the signal
transduction capacity of the BMPR1B variant Arg31Cys,
which is associated with ACD du Pan type in our patient
(Fig. 3a). We compared its activity to the previously de-
scribed BMPR1B mutation Cys53Arg, which is associ-
ated with ACD Grebe type and to Arg31His, another
allele listed in genomic databases [9]. The WT receptor
induced the luciferase expression approximately 8-fold
compared to a control vector and was strongly stimu-
lated by the presence of recombinant GDF5. BMPR1B
Arg31Cys showed only moderate activity when no ligand
was used for stimulation (less than 2-fold). Arg31His in-
duced the SMAD signaling pathway approximately 5-fold,
but remained significantly less active than the WT receptor.
SMAD1/5/8 activation via the BMPR1B variants Arg31His
and Arg31Cys was significantly increased upon ligand
stimulation. However, BMPR1B Arg31Cys still could not
accomplish the level of BMPR1B Arg31His or BMPR1B
WT, pointing to a partial loss of function. In line with pre-
vious findings BMPR1B Cys53Arg exhibited no SMAD ac-
tivity and could not be stimulated by GDF5 either.
Confocal microscopy showed that all investigated BMPR1B
variants are translocated to the cell surface (Fig. 3b).
Discussion
We have identified the homozygous BMPR1B missense
mutation p.Arg31Cys in a patient with ACD du Pan
type. Previously, GDF5 mutations have been shown to
constitute the major cause of ACD Grebe and du Pan
types [3–6], and BMPR1B mutations had been identified
in single families with Grebe syndrome and a Grebe
dysplasia-like phenotype with genital anomalies [8, 9].
However, whether BMPR1B mutations, presumably mu-
tations with milder functional effects, can also cause du
Pan dysplasia was unknown. The following evidence
supports a diagnosis of du Pan dysplasia in the proposita
Fig. 2 3D models for Arg31 substitutions in human BMPR1B. a Structure of the extracellular domain of BMPR1B (green) bound to GDF5 (grey).
Position 31 is indicated with the C-atoms colored in magenta. b Model of the BMPR1B variant Arg31Cys. The unpaired cysteine residue located in
β-strand 1 is highlighted in magenta; the five disulfide bonds formed in BMPR1B WT are shown as yellow sticks and are marked accordingly. c As
in (b) but with an alternative disulfide bond network. The close proximity of the introduced cysteine residue at position 31 to the native residues
Cys32, Cys47, Cys53, and Cys71 potentially leads to an alternative connectivity, which could then alter the conformation of the loops. If Cys31
connects to Cys47 an alternative non-native disulfide bond between Cys34 and Cys71 might be formed, which alters the conformation of the
β1β2-loop important in the recognition and binding of BMP ligands. d Model of the BMPR1B variant Arg31His. The shorter histidine side chain
places the hydrogen bond donor and acceptor groups of the imidazole ring in close proximity to Ser48 and Asn100 allowing to form new
hydrogen bonds with the latter two residues thereby possibly altering the conformation of β-strand 2 and the β1β2-loop
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normal appearing radius, ulna and femur including the
corresponding joints; mal-shaped but present phalangeal
bones of the hands; normal length of the second metacar-
pal; and milder involvement of the tarsals, metatarsals,Fig. 3 The Arg31Cys substitution in BMPR1B causes a moderate loss of funct
the indicated HA-tagged variants of Bmpr1b with the luciferase constructs BR
GDF5. BMPR1B WT strongly induced luciferase activity. The variant BMPR1B Ar
activated after GDF5 treatment but could not accomplish the level of BMPR1B
BMPR1B WT. BMPR1B Cys53Arg did not activate SMAD signaling at all. Data w
and analyzed using a One-Way-ANOVA with subsequent Bonferroni's Multiple
were transfected with the indicated HA-tagged Bmpr1b variants. Using an ant
microscopy. DAPI was used for staining of cell nuclei. All BMPR1B variants weand phalangeal bones of the toes. In Grebe and Hunter-
Thompson ACD the clinical and radiological manifesta-
tions are more severe: the humerus, radius and ulna are
short and bowed, the hand bones are more deformed or
missing and the elbow and knee joints are affected. Thus,ion. a NIH/3 T3 cells were co-transfected with the empty vector pCS2+ or
E-pLG3ti and pRL-TK and stimulated with 2 nM of human recombinant
g31Cys showed nearly no activity without ligand stimulation. It was
WT. Arg31His induced signaling, but considerably lower compared to
ere tested for normal distribution (Kolmogorov-Smirnoff normality test)
Comparison Test (n = 8; ns not significant, *** p < 0.001). b NIH/3 T3 cells
i-HA antibody the expression of BMPR1B could by visualized via confocal
re translocated to the cell membrane
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can be caused by BMPR1B mutations in rare cases. While
the number of affected individuals with ACD due to
BMPR1B mutations is small, our previous [9] and present
results indicate a possible genotype-phenotype correlation
according to which BMPR1B mutations with a strong
functional effect would cause Grebe syndrome, while
milder mutations would result in the clinically and radio-
logically milder du Pan dysplasia.
Indeed, when the Arg31Cys mutation or the Arg31His
variant are compared with other BMPR1B mutations,
e.g., the Cys53Arg exchange [9], the assumed impact of
a missense substitution at position 31 on structure and
BMP binding seems rather moderate. The substitution
of Cys53 not only disrupts the structure-stabilizing di-
sulfide bond network, but also likely causes local unfold-
ing in the center of the BMPR1B ligand-binding domain
due to strong van der Waals overlaps from introducing a
bulky, charged arginine side chain into the tightly
packed hydrophobic core around Cys53. In contrast, the
side chain of Arg31 faces the protein surface being sur-
rounded by bulk solvent. Thus, exchanges against most
other amino acid types will likely not alter the structure
of the BMPR1B ligand-binding domain. Furthermore the
residue at position 31 does not contact GDF5, thus only
amino acid substitutions that (indirectly) cause a con-
formational rearrangement of ligand-binding loops can
affect BMP binding.
A luciferase reporter gene assay indeed revealed that
both BMPR1B variants, Arg31Cys and Arg31His, can
still be stimulated by GDF5 but signal with diminished
biological activity compared to BMPR1B WT. This
suggests that the exchanges at position Arg31 have for
that matter only moderate functional effect and do not
completely prevent ligand binding, as it is the case for
Cys53Arg.
Conclusion
In conclusion, we provide evidence for a causal role of a
hypomorphic BMPR1B missense mutation in du Pan
dysplasia, thereby broadening the clinical and molecular
overlap between ACD types. This finding also has obvi-
ous implications for molecular diagnostic strategies, as
BMPR1B sequencing should be considered in patients
with ACD harboring no mutations in GDF5.
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